Review Series Pushes for Routine Lipoprotein(a) Testing and Treatment
This paper, part of a four-article series in the European Cardiology Review, argues that lipoprotein(a) [Lp(a)] is an underappreciated, genetically determined cardiovascular risk factor that deserves wider clinical attention—covering its biology, risk implications, and emerging treatment approaches. No abstract was available, so this summary is based on the paper's title and the surrounding discussion rather than its full claims or methodology. The broader series compiles perspectives from cardiology and lipid experts on measuring and managing Lp(a) in practice. A cardiologist promoting the series on Twitter framed it as an essential primer, tagging cardiovascular and lipid-focused organizations and calling the four linked papers 'truly brilliant.' The commentary was promotional rather than critical, with no substantive scientific pushback appearing in the discussion.
- Lipoprotein(a): It is Time to Understand and Treat this Cardiovascular Risk Factor
- Lipoprotein(a): It is Time to Understand and Treat this Cardiovascular Risk Factor
- Lipoprotein(a): It is Time to Understand and Treat this Cardiovascular Risk Factor
- Lipoprotein(a): It is Time to Understand and Treat this Cardiovascular Risk Factor
Discussion: 1 tweets from 1 authors · @DrDerekConnolly